Hence, primary resistance of BRAF-mutant thyroid cancer cell lines to vemurafenib is overcome by HER kinase inhibitors and further abrogated by YAP inhibition in vitro and in vivo. The gene discussed is BRAF; the disease is thyroid cancer.